Profile data is unavailable for this security.
About the company
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
- Revenue in USD (TTM)1.13m
- Net income in USD-19.39m
- Incorporated2020
- Employees8.00
- LocationCyclo Therapeutics Inc6714 Nw 16Th Street, Suite BGAINESVILLE 32653United StatesUSA
- Phone+1 (386) 418-8060
- Websitehttps://www.cyclotherapeutics.com/
Mergers & acquisitions
Acquired company | CYTH:NAQ since announced | Transaction value |
---|---|---|
Applied Molecular Transport Inc | -24.38% | 11.94m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equillium Inc | 37.89m | -12.13m | 23.34m | 44.00 | -- | 1.11 | -- | 0.6159 | -0.3476 | -0.3476 | 1.08 | 0.5983 | 0.6568 | -- | 8.95 | 861,227.30 | -21.02 | -46.81 | -39.66 | -57.36 | -- | -- | -32.01 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
Rapid Micro Biosystems Inc | 23.10m | -51.90m | 25.85m | 193.00 | -- | 0.2436 | -- | 1.12 | -1.20 | -1.20 | 0.5355 | 2.48 | 0.1535 | 1.37 | 4.34 | 119,663.20 | -34.49 | -- | -38.20 | -- | -22.59 | -- | -224.73 | -- | 5.62 | -- | 0.0028 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
Vyne Therapeutics Inc | 423.00k | -28.50m | 26.59m | 10.00 | -- | 0.3139 | -- | 62.85 | -5.26 | -5.42 | 0.021 | 5.83 | 0.0067 | -- | -- | 42,300.00 | -44.91 | -108.41 | -50.67 | -138.57 | -- | -- | -6,738.06 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
Acasti Pharma Inc | 0.00 | -12.85m | 27.26m | 32.00 | -- | 0.4415 | -- | -- | -1.46 | -1.46 | 0.00 | 6.57 | 0.00 | -- | -- | -- | -16.86 | -31.68 | -17.45 | -33.95 | -- | -- | -- | -56,271.43 | -- | -6.18 | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 31.82m | 1.00 | -- | 0.1776 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
Aadi Bioscience Inc | 23.84m | -68.83m | 34.38m | 75.00 | -- | 0.38 | -- | 1.44 | -2.55 | -2.55 | 0.8848 | 3.68 | 0.1692 | 0.6021 | 4.54 | 267,865.20 | -48.86 | -50.25 | -56.39 | -56.15 | 87.70 | -- | -288.72 | -473.97 | 4.86 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
Natural Alternatives International, Inc. | 120.20m | -3.31m | 34.48m | 317.00 | -- | 0.41 | 25.69 | 0.2868 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
Cyclo Therapeutics Inc | 1.13m | -19.39m | 34.91m | 8.00 | -- | 57.23 | -- | 30.99 | -1.03 | -1.03 | 0.0557 | 0.0213 | 0.2001 | 0.4155 | 11.12 | 140,806.30 | -344.43 | -132.22 | -17,225.46 | -215.17 | 91.02 | 90.37 | -1,721.63 | -1,114.04 | 0.968 | -- | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
Lexaria Bioscience Corp | 404.72k | -5.44m | 37.81m | 5.00 | -- | 5.02 | -- | 93.43 | -0.6851 | -0.6851 | 0.0493 | 0.5264 | 0.0722 | -- | 1.64 | 80,944.00 | -97.62 | -95.67 | -94.18 | -96.58 | 95.66 | 76.98 | -1,351.64 | -1,612.76 | -- | -175.33 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
Fortress Biotech Inc | 85.11m | -62.86m | 39.50m | 186.00 | -- | 1.48 | -- | 0.464 | -6.65 | -6.65 | 7.96 | 1.19 | 0.3976 | 2.27 | 4.55 | 457,602.20 | -64.47 | -52.50 | -107.85 | -99.46 | 68.25 | 63.17 | -162.17 | -236.94 | 1.21 | -10.18 | 1.07 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
Qilian International Holding Group Ltd | 46.47m | -7.78m | 40.25m | 298.00 | -- | 0.9407 | -- | 0.8662 | -1.09 | -1.09 | 6.50 | 5.98 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
Ocuphire Pharma Inc | 19.01m | -11.30m | 40.96m | 14.00 | -- | 0.8606 | -- | 2.15 | -0.4867 | -0.4867 | 0.8366 | 1.84 | 0.391 | -- | 4.52 | 1,357,929.00 | -23.24 | -58.31 | -25.89 | -65.94 | -- | -- | -59.44 | -137.92 | -- | -7.80 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
Eyenovia Inc | 8.78k | -32.44m | 42.23m | 57.00 | -- | 20.03 | -- | 4,809.50 | -0.7448 | -0.7448 | 0.0002 | 0.0384 | 0.0003 | -- | 0.008 | 154.04 | -116.94 | -80.31 | -190.14 | -117.70 | 0.00 | -- | -369,519.70 | -680.95 | 0.6645 | -16.03 | 0.8914 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
Incannex Healthcare Inc | -100.00bn | -100.00bn | 43.49m | -- | -- | 3.08 | -- | -- | -- | -- | -- | 0.8907 | -- | -- | -- | -- | -- | -54.94 | -- | -59.47 | -- | -- | -- | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
United-Guardian, Inc. | 11.57m | 2.75m | 44.03m | 25.00 | 16.01 | 3.94 | 15.42 | 3.81 | 0.5987 | 0.5987 | 2.52 | 2.43 | 0.926 | 3.17 | 6.40 | 462,790.80 | 22.02 | 29.84 | 25.94 | 34.39 | 48.64 | 55.31 | 23.78 | 28.79 | 5.99 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
Holder | Shares | % Held |
---|---|---|
EPIQ Capital Group LLCas of 31 Mar 2024 | 853.82k | 2.98% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 396.66k | 1.39% |
Geode Capital Management LLCas of 31 Mar 2024 | 159.75k | 0.56% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 39.53k | 0.14% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 36.50k | 0.13% |
Renaissance Technologies LLCas of 31 Mar 2024 | 21.76k | 0.08% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 21.74k | 0.08% |
Wealth Enhancement Advisory Services LLCas of 31 Mar 2024 | 20.40k | 0.07% |
Tower Research Capital LLCas of 31 Mar 2024 | 6.58k | 0.02% |
UBS Financial Services, Inc.as of 31 Mar 2024 | 4.53k | 0.02% |